This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg/m\^2).
No evidence of active or chronic disease as determined by detailed medical and surgical history and the results of a physical examination, vital signs, 12 lead electrocardiogram (ECG), or clinical laboratory tests
BMI ≥23 kg/m² at screening
Agreement to adhere to the contraception requirements
History of acute or chronic pancreatitis
History of clinically significant gallbladder disease in the opinion of the investigator
History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder
History or presence of an abnormal ECG that is deemed clinically significant in the opinion of the investigator